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Objectives: Vasoplegia is a frequent complication after cardiopulmonary bypass that
often requires the application of norepinephrine. In a number of cases, however,
vasoplegia is refractory to norepinephrine. The guanylate cyclase inhibitor methyl-
ene blue could be an attractive treatment alternative in such cases. This study
examines the results of methylene blue therapy for norepinephrine-refractory va-
soplegia after cardiopulmonary bypass.
Methods: A total of 54 patients with norepinephrine-refractory vasoplegia after
cardiopulmonary bypass were treated with methylene blue (2 mg/kg) administered
intravenously through a period of 20 minutes. The effects on hemodynamics,
norepinephrine dosage, and clinical outcome were evaluated.
Results: Three patients (5.6%) died during the hospital stay. A clinically relevant
increase in systemic vascular resistance and a decrease in norepinephrine dosage
were observed in 51 patients within 1 hour after methylene blue infusion. Four
patients (7.4%) had no response to methylene blue. No adverse effects related to
methylene blue were observed.
Conclusions: A single dose of methylene blue seems to be a potent approach to
norepinephrine-refractory vasoplegia after cardiopulmonary bypass for most pa-
tients, with no obvious side effects. Guanylate cyclase inhibitors could be a novel
class of agents for the treatment of norepinephrine-refractory vasoplegia after
cardiopulmonary bypass. A controlled clinical trial is now needed to evaluate the
role of methylene blue in this situation.
After surgery with cardiopulmonary bypass (CPB) support, lowperipheral vascular resistance may result in high vasopressiverequirements to maintain sufficient mean arterial blood pressure.The underlying mechanisms that regulate the decreased vasculartone are unclear and remain a subject of intense research anddebate.1-9 The reported incidence of a hyperdynamic state with
low systemic vascular resistance (SVR) is as great as 10% among all patients after
cardiac surgical intervention with CPB support.6 In most cases low-dose norepi-
nephrine application is sufficient to restore adequate SVR. In some cases, however,
prolonged vasoplegia is resistant to norepinephrine. These patients have been
treated with the intravenous application of vasopressin, as shown by Argenziano and
colleagues.10 However, this approach has not been validated.
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Recently, several cases have been described in the liter-
ature by us and by others in which the guanylate cyclase
inhibitor methylene blue (MB) was successfully adminis-
tered intravenously to reverse norepinephrine-resistant va-
soplegia after CPB.11-14 The available data have been ob-
tained from anecdotal case observations only, however, and
the effect of MB has not been examined in larger cohorts.
Here we report our experience with the use of MB for
norepinephrine-refractory post-CPB vasoplegia in a cohort
of 54 patients.
Material and Methods
Patients
Between October 2000 and October 2001, a total of 1111 various
operation with CPB support were performed. In 4.8% of these
cases (n  54/1111), norepinephrine-refractory systemic vasople-
gia developed. Norepinephrine-refractory systemic vasoplegia was
defined as a mean arterial blood pressure lower than 60 mm Hg, a
cardiac output greater than 4.0 L/min, low SVR (600 dyne · s ·
cm5) under intravenous norepinephrine infusion (0.5 g · kg1
· min1). These 54 patients (41 [76%] male, mean age 56.7 15.1
years) received the guanylate cyclase inhibitor MB in addition to
norepinephrine for restoration of mean systemic blood pressure.
Patients with active endocarditis were excluded from the cohort.
No other medications were applied to treat low SVR, including
vasopressin, phenylephrine hydrochloride, or corticosteroids.
Anesthesia, CPB, and Surgery
Anesthesia was induced with etomidate (0.3 mg/kg) and sufentanil
(0.8 g/kg) and maintained with continuous administration of
sufentanil and propofol during surgery. Pancuronium bromide was
used for neuromuscular blockade. In all cases Sto¨ckertTM roller
pumps (Sto¨ckert Instrumente GmbH, Munich, Germany) and
membrane oxygenators (Minpech; BioCor, LLC, Yardley, Pa)
primed with 1000 mL Ringer solution, 300 mL 5% glucose, and 40
mL 8.4% sodium bicarbonate were used for CPB.
A nonpulsatile pump flow was maintained at 2.4 L · min · m2
with a perfusion pressure of 60 to 80 mm Hg. CPB was initiated
at moderate hypothermia (30°C-32°C). For cardioplegia, St
Thomas solution or intermittent cold blood cardioplegia was used.
Initial heparinization was accomplished with 300 IU/kg body
weight and was supplemented as required to maintain an activated
clotting time longer than 400 seconds. All procedures were per-
formed with the use of aprotinin according to the Hammersmith
protocol.15 The intraoperative variables and operations performed
are depicted in Table 1.
Postoperative Treatment
In cases of postoperative hemodynamic instability despite ade-
quate fluid substitution, a thermodilution catheter was inserted and
norepinephrine infusion was initiated according to the cardiac
output and SVR. If hemodynamic instability in patients with
high-output circulatory failure persisted despite norepinephrine
infusion (0.4 g · kg1 · min1) and fluid substitution, a single
dose of MB (2 mg/kg) was administered intravenously (infusion
time of 20 minutes).
Hemodynamic Measures
Mean arterial pressure, mean pulmonary arterial pressure, mean
right atrial pressure, mean left atrial pressure, and cardiac output
were recorded, and the SVR was calculated according to a standard
formula. All measurements and calculations were performed im-
mediately before MB infusion and 1, 6, and 12 hours thereafter.
Postoperative Follow-up
Complete postoperative follow-up was obtained in all cases. As a
gross evaluation of pulmonary function the duration of mechanical
ventilation and the ratio of PaO2 to inspired oxygen fraction were
determined before MB infusion and 1, 6, and 12 hours thereafter.
For evaluation of organ function, routine laboratory indices, in-
cluding serum concentrations of creatinine, aspartate aminotrans-
ferase, alanine aminotransferase, and lactate, were assessed before
MB administration and 1, 6, 12, 24, and 48 hours thereafter.
Statistical Analysis
Continuous variables are expressed as mean  SD unless other-
wise indicated. The Friedmann test was used for comparisons of
means within the group. Intragroup comparisons of values at
sequential time points at different times were done with the Wil-
coxon test for nonnormally distributed data. Statistical calculations
were performed with the SPSS software package for Windows
(SPSS Inc, Chicago, Ill).
Results
MB was administered 136  48 minutes after surgery and
51  28 minutes after initiation of norepinephrine infusion
to stabilize the hemodynamic situation. In all cases MB
infusion was initiated when a norepinephrine dosage of at
least 0.5 g · kg1 · min11 was reached. Hemodynamic
measures are depicted in Table 2. Immediately after MB
infusion, clinically significant increases in mean arterial
pressure and SVR combined with a significant decrease in
norepinephrine dosage (before MB vs. 1 hour after MB P
.001, before MB vs. 6 hours after MB P  .001, before MB
vs. 12 hours after MB P  .001) were seen in 92.4% of
patients (Figure 1). The cardiac output decreased after MB
TABLE 1. Intraoperative variables and surgical procedures
Bypass time (min, mean  SD) 167 80
Aortic crossclamp time (min, mean  SD) 94 77
Temperature (°C, mean  SD) 30.5 1.7
Surgical procedures (No.)
Coronary artery bypass grafting 15
Reoperative coronary artery bypass grafting 1
Coronary artery bypass grafting with valve surgery 4
Aortic valve surgery 3
Mitral valve surgery 6
Tricuspid valve surgery 1
Double valve surgery 6
Heart transplantation 7
Double-lung transplantation 2
Left ventricular assist device placement 3
Miscellaneous 6
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infusion in parallel with the increase in SVR. Mean pulmo-
nary arterial pressure, mean right atrial pressure, and mean
left atrial pressure did not change with time after MB
infusion. Data from patients who did not have a response to
MB are depicted in Table 3.
The serum creatinine concentration and the pulmonary
gas exchange, expressed as the ratio of PaO2 to inspired
oxygen fraction, remained unaffected by MB (Table 4).
However, the serum aspartate aminotransferase and alanine
aminotransferase concentrations, which were already in-
creased before MB infusion, increased further during the
next 48 hours after MB infusion. The serum lactate concen-
tration decreased significantly within 12 hours after MB
infusion (Table 4).
Three patients died during the hospital stay (5.6%). In a
51-year-old male patient with dilated cardiomyopathy and
preoperative low cardiac output, a left ventricular assist
device was implanted as a bridge to transplantation. This
patient did not respond to MB and died of multiorgan failure
on the third postoperative day. The second patient, a 71-
year-old man, had norepinephrine-refractory vasoplegia de-
velop after double valve replacement. After MB infusion,
the SVR increased and the norepinephrine dosage could be
reduced significantly. This patient had renal failure requir-
ing hemodialysis develop and died of septic shock on the
sixth postoperative day. The third patient was a 66-year-old
man with unstable angina who underwent coronary artery
bypass grafting. He was resuscitated 6 hours after the op-
TABLE 2. Hemodynamic data
Variable
Time points P values
Before MB
1 h after
MB
6 h after
MB
12 h after
MB
Before vs.
1 h after MB
Before vs.
6 h after MB
Before vs.
12 h after MB
Mean arterial pressure
(mm Hg)
68 9 72 12 71 9 73 10 .02 .02 .02
Mean pulmonary artery
pressure (mm Hg)
23 6 24 7 25 5 24 8 .1 .1 .1
Mean right atrial
pressure (mm Hg)
14 4 14 4 15 4 15 5 .1 .1 .1
Mean left atrial pressure
(mm Hg)
11 4 10 3 12 5 10 5 .09 .08 .09
Cardiac output (L/min) 7.6 3.1 6.5 2.8 6.1 2.4 5.8 1.9 .001 .001 .001
SVR (dyne · s · cm5) 547 108 766 194 796 153 876 184 .001 .001 .001
Figure 1. Persistent increase in mean arterial pressure (mAP) (before vs. 1 hour after MB P .02, before vs. 6 hours
after MB P .02, before vs. 12 hours after MB P .02) and clinically significant increase in SVR (before vs. 1 hour
after MB P < .001, before vs. 6 hours after MB P < .001, before vs. 12 hours after MB P < .001) combined with
significant decrease in norepinephrine dosage (before vs. 1 hour after MB P < .001, before vs. 6 hours after MB
P < .001, before vs. 12 hours after MB P < .001) were observed after single intravenous dose of MB.
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eration because of acute myocardial ischemia and was sent
back to the operating room for additional coronary bypass
grafting. He could not be weaned from CPB, and a left
ventricular assist device was implanted. After the second
operation, he had norepinephrine refractory vasoplegia de-
velop that did not respond to MB. He died of multiorgan
failure on the 12th postoperative day.
Six patients had coagulopathy develop. One of these
patients underwent reexploration for excessive bleeding and
died on the third postoperative day.
Four patients required renal dialysis (8%) during the
postoperative course. Two of them died. Two of these
patients were already receiving hemodialysis before the
operation. The mean intensive care unit stay of all patients
was 11  8 days (range 1-42 days). The mean mechanical
ventilation time was 212 172 hours (range 14-794 hours).
Most patients (82%, n  44/54) required mechanical ven-
tilation for more than 48 hours after the operation.
Discussion
We have shown the intravenous application of MB to be
highly effective in the treatment of norepinephrine-refrac-
tory vasoplegia after CPB, with no relevant side effects.
According to the literature, MB has chiefly been used to
treat patients with septic shock and low peripheral vascular
resistance.16,17 The effectiveness of MB in cardiac surgery
has only been described in anecdotal case reports by us and
others.11-14 To our knowledge, this is the first large-scale
investigation with postoperative human subjects in which
severe vasoplegia after CPB was treated with MB.
A few adverse effects of MB in the treatment of norepi-
nephrine-refractory vasoplegia have been described, such as
cardiac arrhythmias; coronary vasoconstriction; decreases
in cardiac output, renal blood flow, and mesenteric blood
flow; increases in pulmonary vascular pressure and resis-
tance; and deterioration in gas exchange. However, most of
these side effects are dose dependent and do not occur when
a dose of MB no greater than 2 mg/kg is administered.18-21
In our patients none of the mentioned side effects were
observed. In contrast, we found a significant decrease in
arterial serum lactate concentration within 24 hours after
MB infusion, underlining the restoration of normal periph-
eral blood flow after MB infusion. Although we noticed
significant increases in serum levels of aspartate amino-
transferase and alanine aminotransferase after application of
MB, it remains a matter of speculation whether this increase
is related to the application of the drug or is an effect of the
accompanying high norepinephrine dosage. Several reports
have demonstrated that norepinephrine-refractory vasople-
gia alone is associated with a higher postoperative morbid-
ity.22-24 Furthermore, the duration of norepinephrine-refrac-
tory vasoplegia may be an important factor influencing the
TABLE 3. Data from patients without response to MB infusion
Case
Age
(y) Sex Diagnosis Operation
Bypass
(min)
Aortic
crossclamp
(min)
Temperature
(°C) Outcome
1 51 Male DCM LVAD 183 143 28 Dead
2 66 Male Unstable angina CABG and LVAD 205 128 32 Dead
3 64 Male AV and MV stenosis AV and MV replacement 164 120 30 Alive
4 63 Male DCM Heart transplantation 115 — 30 Alive
DCM, Dilated cardiomyopathy; LVAD, left ventricular assist device; CABG, coronary artery ypass grafting; AV, aortic valve; MVR, mitral valve.
TABLE 4. Laboratory findings and gas exchange
Variable
Time points P values
Before
MB
1 h after
MB
6 h after
MB
12 h after
MB
24 h after
MB
48 h after
MB
Before
vs. 1 h
after MB
Before
vs. 6 h
after MB
Before
vs. 12 h
after MB
Before
vs. 24 h
after MB
Before
vs. 48 h
after MB
Creatinine (mol/L) 160 107 163 98 168 106 172 113 185 116 169 99 .1 .1 .1 .06 .1
Aspartate
aminotransferase
(U/L)
550 240 749 355 767 420 890 471 993 502 764 358 .001 .001 .001 .001 .001
Alanine
aminotransferase
(U/L)
473 194 505 203 606 276 609 287 532 314 508 235 .08 .001 .001 .05 .08
Lactate (mmol/L) 6.4 2.7 6.2 2.5 5.8 4.8 5.5 4.1 3.6 3.3 2.7 1.9 .1 p 0.1 0.04 .001 .001
PO2/inspired oxygen 1.44 0.73 1.41 0.55 1.8 0.88 2.22 0.51 — — .34 .04 .011 — —
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outcome. Gomes and coworkers24 showed in a small series
of patients that norepinephrine-refractory vasoplegia per-
sisting longer than 36 to 48 hours is associated with in-
creases in morbidity and mortality. Thus an aggressive and
fast treatment of postoperative norepinephrine-refractory
vasoplegia is mandatory to reduce postoperative morbidity
and mortality. Four of our patients had no response to MB,
and 2 of them died. The reason could not be elucidated from
our data and remains a matter of speculation. However, a
persistent release of proinflammatory mediators as a result
of placement of a left ventricular assist device system could
explain this phenomenon in 2 of the 4 who had no response.
The underlying mechanisms that are involved in the
regulation of post-CPB vasoplegia are a matter of contro-
versy but may be related to the activation of an inflamma-
tory response.1-9 The favorable effect of MB demonstrated
in this study suggests that refractory vasoplegia after CPB
may reflect a dysregulation of nitric oxide synthesis and
vascular smooth muscle cell guanylate cyclase activation. In
recent studies an increase in nitric oxide release after CPB
could not be demonstrated.7,25 Therefore it can be hypoth-
esized that the CPB-triggered release of proinflammatory
mediators may act through the induction of the final com-
mon pathway of nitric oxide, which is the activation of the
guanylate cyclase, leading to vasodilation, as shown by Wu
and coworkers.26 This group showed that the hyporespon-
siveness to norepinephrine in a hypercirculatory state is due
to the activation of the soluble guanylate cyclase, which in
part is mediated by nitric oxide. Even more supportive of
the hypothesis that post CPB vasodilation is nitric oxide
independent is the finding described by Beasley and
McGuiggin27 and Schmidt28 that interleukin 1 and oxygen
free radicals may activate the soluble guanylate cyclase
leading to vascular hyporeactivity in the absence of nitric
oxide. Because cytokines and free radicals are produced
during CPB, a nitric oxide–independent activation of the
guanylate cyclase could be an initiator of refractory va-
soplegia after CPB.
This was an observational study with no control group.
However, an immediate increase in SVR and an immediate
clinically significant decrease in norepinephrine dosage
were observed in 92% of our patients after a single dose of
MB, with no side effects related to the drug. Thus we were
reluctant to withhold this new treatment modality from
patients with norepinephrine-refractory vasoplegia after
CPB, because the only alternative for these patients is the
maintenance or even increase of the norepinephrine dosage,
with the known side effect of reduced microperfusion of the
visceral organs.
In conclusion, the inhibition of the soluble guanylate
cyclase elicited by nitric oxide or any endothelially soluble
guanylate cyclase activating factor (eg, interleukin 1, atrial
natriuretic peptide, and bradykinin) could be a novel ap-
proach in the treatment of norepinephrine-refractory va-
soplegia after CPB. We recommend the use of MB in such
cases. For final judgment of this novel concept, however, a
prospective randomized study is desirable. Furthermore, the
effects of MB in the treatment of norepinephrine-refractory
vasoplegia after CPB should be compared with those of
other agents, such as vasopressin.
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